 |
Established in 1976 by grateful patients and their friends and families, the Samuel Waxman Cancer Research Foundation is a non-profit, 501(c)(3), international organization that is dedicated to supporting a focused research program to develop targeted cancer cell-specific therapies with minimal toxicity, such as differentiation therapy. Differentiation therapy, already successful with acute promyelocytic leukemia (APL), is based on the correction of defects in growth, differentiation and death that are characteristic of cancer cells.
The Samuel Waxman Cancer Research Foundation is unique in that its research is not disease-specific but concept driven. The Foundation has already proven that non-toxic differentiation therapy is a powerful way to treat leukemia, having discovered two drugs that are now used worldwide. The Foundation's investigators are considered leaders in the study of differentiation and publish their findings in many major scientific journals in the United States and abroad.
View Map
|
|
